The application for the renewal of the approval of the active substance S-abscisic acid was submitted on 29 September 2021 and the rapporteur Member State informed the co-rapporteur Member State, the Commission and the Authority on 11 April 2022 that it had assessed the admissibility pursuant to Article 8 of Implementing Regulation (EU) 2020/1740, and in particular its completeness and timeliness, and concluded that it was admissible. The application has been made public by the Authority, which conducted a public consultation on it between 24 October and 22 December 2023, pursuant to Article 10 of Implementing Regulation (EU) 2020/1740. The rapporteur Member State has not finalised the risk assessments pursuant to Article 11 of Implementing Regulation (EU) 2020/1740 and estimates that it will be able to submit the draft renewal assessment report to the Commission and the Authority by the end of December 2026. As additional time is necessary to complete the remaining steps in the renewal procedure, the duration of the extension of the approval period should be set at 31 months, until 15 April 2029.
Recital 45, Regulation (EU) 2026/1826
In forcesince 28 Jul 2026